Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: A case-control study

Journal of Clinical Pathology

Volumn 59, Issue 2, 2006, Pages 166-173

  Massi, D ^a   Puig, S ^b   Franchi, A ^a   Malvehy, J ^b   Vidal Sicart, S ^b   Gonzalez Cao M ^b   Baroni, G ^a   Ketabchi, S ^a   Palou, J ^b   Santucci, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; VASCULOTROPIN C;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MALE; MELANOMA; MORPHOMETRICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SENTINEL LYMPH NODE; SURVIVAL; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 32544438494     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.028431     Document Type: Article

References (37)

1. Rigel DS. Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment. CA Cancer J Clin 1996;46:195-8.
2. Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003. CA Cancer J Clin 2003;53:5-26.
3. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62-70.
4. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
5. WHO. WHO declares lymphatic mapping to be the standard of care for melanoma. Oncology 1999;13:288.
6. Pepper MS, Skobe M. Lymphatic endothelium: morphological, molecular and functional properties. J Cell Biol 2003;163:209-13.
7. de Waal RMW, van Altena MC, Erhard H, et al. Lack of lymphangiogenesis in human primary cutaneous melanoma. Am J Pathol 1997;150:1951-7.
8. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001;7:462-8.
9. Clarijs R, Ruiter DJ, de Waal RM. Lymphangiogenesis in malignant tumours: does it occur? J Pathol 2001;193:143-6.
10. Padera TP, Kadambi A, Di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
11. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001;159:893-903.
12. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573-83.
13. Schoppmann SF, Birner P, Studer P, et al. Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 2001;21:2351-5.
14. Beasley NJP, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315-20.
15. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Flt-4-positive vessel density correlates with vascular endothelial growth factor-D expression, nodal status, and prognosis in breast cancer. Clin Cancer Res 2003;9:5313-17.
16. Franchi A, Gallo O, Massi D, et al. Tumor lymphangiogenesis in head and neck squamous carcinoma. Cancer 2004;101:973-8.
17. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 2005;18:143-52.
18. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786-90.
19. Dadras SS, Paul T, Bertoncini J, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951-60.
20. Shields JD, Borsetti M, Rigby H, et al. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004;90:693-700.
21. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density of low-grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003;9:250-6.
22. Vidal-Sicart S, Pons F, Puig S, et al. Identification of the sentinel lymph node in patients with malignant melanoma: what are the reasons for mistakes? Eur J Nucl Med Mol Imaging 2003;30:362-6.
23. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-78.
24. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002;15:434-40.
25. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-7.
26. Fogt F, Zimmerman RL, Ross HM, et al. Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2-40. Oncol Rep 2004;11:47-50.
27. Birner P, Schindl M, Obermair A, et al. Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer 2001;95:29-33.
28. Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-56.
29. Giorgadze TA, Zhang PJ, Pasha T, et al. Lymphatic vessel density is significantly increased in melanoma. J Cutan Pathol 2004;31:672-7.
30. Valencak J, Heere-Ress E, Kopp T, et al. Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma. Eur J Cancer 2004;40:358-64.
31. Straume O, Akslen LA. Lymphatic vessel density and prognosis in cutaneous melanoma [letter]. Br J Cancer 2004;91:1224-5.
32. Sleeman JP, Krishnan J, Kirkin V, et al. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech 2001;55:61-9.
33. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105-10.
34. Lubach D, Ludemann W, Berens von Rautenfeld D. Recent findings on the angioarchitecture of the lymph vessel system of human skin. Br J Dermatol 1996;135:733-7.
35. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20:672-82.
36. Mattila MM, Ruohola JK, Karpanen T, et al. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 2002;98:946-51.
37. Schietroma C, Cianfarani F, Local PM, et al. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 2003;98:789-97.